InfuSystems Holdings, Inc.
10.52+0.07 (+0.67%)
Oct 29, 4:00:00 PM EDT · NYSE American · INFU · USD
Key Stats
Market Cap
214.88MP/E (TTM)
43.83Basic EPS (TTM)
0.24Dividend Yield
0%Recent Filings
8-K
Q3 2025 earnings preview
InfuSystem Holdings announced on October 28, 2025, that it will release third quarter 2025 financial results before the market opens on November 4, 2025, followed by a conference call at 9:00 a.m. Eastern Time. Investors can join via dial-in or live webcast on the company's IR site. This routine disclosure keeps stakeholders updated on performance in oncology, pain management, and wound therapy services. No results yet.
8-K
Investor update signals growth
InfuSystem Holdings released its October 6, 2025 investor presentation, highlighting six years of record revenue growth to $134.9 million in 2024, with adjusted EBITDA at $25.3 million. The company projects 2025 revenue of $139.9 million and adjusted EBITDA of $29.7 million, fueled by expansions in biomedical services and wound care partnerships. Solid cash flow supports opportunistic share repurchases and debt reduction. Growth hinges on executing new initiatives amid reimbursement risks.
10-Q
Q2 FY2025 results
InfuSystem Holdings posted solid Q2 FY2025 results, with net revenues climbing 6.8% year-over-year to $36.0M, fueled by 6.3% growth in Patient Services to $21.5M and 7.7% in Device Solutions to $14.5M; gross profit surged 19.2% to $19.9M, lifting the margin to 55.2% from 49.5%, thanks to better procurement and sales mix. Operating income doubled to $3.8M, while diluted EPS held steady at $0.12 on slightly fewer shares after $6.4M in repurchases. Free cash flow hit $4.5M (derived), up sharply from prior periods, with cash at $720K and $48.4M revolver availability against $26.3M debt maturing 2030. The May 2025 Apollo acquisition for $1.4M cash added $1.2M in intangibles to bolster wound care. Yet competition in oncology reimbursement lingers as a key risk.
8-K
Q2 revenues up 7%, EBITDA soars
InfuSystem Holdings reported Q2 2025 net revenues of $36.0 million, up 7% year-over-year, with gross margins expanding 5.7% to 55.2% on stronger oncology and wound care volumes. Net income surged 262% to $2.6 million, while Adjusted EBITDA climbed 32% to $8.0 million at a 22.3% margin, fueled by operational efficiencies and direct rentals. Year-to-date operating cash flow hit $8.8 million, up 227%, supporting $3.5 million in stock repurchases. The company raised its full-year Adjusted EBITDA margin guidance to 20% or higher but trimmed revenue growth to 6-8% due to slower ramps in advanced wound care and chemo mouthpiece reimbursement shifts; a small $1.4 million acquisition bolsters processing tech.
8-K
Q2 2025 earnings announcement
InfuSystem Holdings announced on July 29, 2025, that it will release its second quarter 2025 financial results before the market opens on August 5, 2025, followed by a conference call at 9:00 a.m. Eastern Time. Investors can dial in or access the live webcast via the company's investor relations site, with a replay available for 90 days. This timely disclosure keeps stakeholders informed on the health care service provider's performance amid its focus on outpatient durable medical equipment solutions.
IPO
Website
Employees
Sector
Industry
BAX
Baxter International Inc.
22.42-0.44
ICUI
ICU Medical, Inc.
117.67-2.44
ISRG
Intuitive Surgical, Inc.
537.59-7.80
KRMD
KORU Medical Systems, Inc.
3.95-0.06
MMSI
Merit Medical Systems, Inc.
81.39-1.40
NSYS
Nortech Systems Incorporated
9.59-0.04
NUWE
Nuwellis, Inc.
3.05-0.05
SOLV
Solventum Corporation
69.78-1.14
TFX
Teleflex Incorporated
128.12-2.46
WST
West Pharmaceutical Services, I
284.86+1.37